The portfolio maintains a cost advantage over competitors, priced within the second-lowest fee quintile among peers.
Fidelity Advisor Biotechnology I FBTIX
- NAV / 1-Day Return 35.90 / +1.07 %
- Total Assets 1.7 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.740%
- Distribution Fee Level Below Average
- Share Class Type Institutional
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment —
- Status Open
- TTM Yield 1.24%
- Turnover 78%
USD | NAV as of Jul 26, 2024 | 1-Day Return as of Jul 26, 2024, 10:12 PM GMT+0
Morningstar’s Analysis FBTIX
Will FBTIX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 62.1
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
AbbVie Inc | 19.17 | 314.3 Mil | Healthcare |
Amgen Inc | 9.58 | 157.1 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 8.52 | 139.8 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 7.12 | 116.8 Mil | Healthcare |
Ascendis Pharma A/S ADR | 3.91 | 64.1 Mil | Healthcare |
Alnylam Pharmaceuticals Inc | 3.43 | 56.3 Mil | Healthcare |
argenx SE ADR | 3.41 | 55.9 Mil | Healthcare |
Viking Therapeutics Inc | 2.72 | 44.6 Mil | Healthcare |
Vaxcyte Inc Ordinary Shares | 2.57 | 42.1 Mil | Healthcare |
Cytokinetics Inc | 1.68 | 27.5 Mil | Healthcare |